Tesamorelin, also called Egrifta in the clinical setting, is a growth hormone releasing hormone (GHRH) analogue consisting of standard GHRH to which an additional trans-3-hexanoic acid group has been added. Produced by Theratechnologies of Canada, Tesamorelin became the newest drug to be approved by the FDA for use in HIV-associated lipodystrophy in 2010. The peptide has also been investigated for its ability to improve peripheral nerve regeneration and as a potential intervention for mild cognitive impairment (MCI), the precursor to dementia.
Sermorelin is one of a handful of growth hormone releasing hormone GHRH analogues that have been developed in recent years in an effort to preserve some of the positive effects of natural GHRH while avoiding undesirable effects. Sermorelin (Geref) is currently used clinically to assess growth hormone secretion, but the peptide is of additional interest for its abilities to:
- reduce scarring following heart attack,
- increase bone density,
- improve nutrition in chronic illness,
- improve renal function,
- fight the effects of dementia, and
- reduce seizure activity.